Ivosidenib is an oral targeted therapy used primarily in the treatment of certain types of cancer. It is a small molecule inhibitor specifically designed to target and inhibit mutant isocitrate dehydrogenase 1 (IDH1) enzymes. Mutations in the IDH1 gene are found in various cancers, including acute myeloid leukemia (AML) and cholangiocarcinoma.
